ArticleFrontiers in neurology2019
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Article in Frontiers in neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.Neurology(R) neuroimmunology & neuroinflammation · 2022Pooled it
- Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers.Journal of neurology · 2021Pooled it
- Neurofilaments in progressive multiple sclerosis: a systematic review.Journal of neurology · 2021Pooled it
- Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2021Pooled it
- Effects of disease-modifying drugs on serum neurofilament light chain, chitinase-3-like-1 protein levels, and selected plasmacytoid dendritic cell biomarkers in relapsing-remitting multiple sclerosis.African journal of laboratory medicine · 2026Article
- Plasma CHI3L1 as a marker of cognitive and structural brain changes in radiologically isolated syndrome.BMJ neurology open · 2026Article
- Longitudinal Changes in Neuroaxonal and Inflammatory CSF Biomarkers in Multiple Sclerosis Patients Undergoing Interferon Beta Therapy.Biomedicines · 2025Article
- The emerging role of chitinase-3-like-1 protein in neurodegeneration.Metabolic brain disease · 2025Review
- Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.Molecular neurodegeneration · 2025Review
- No Relation Between Cognitive Impairment, Physical Disability and Serum Biomarkers in a Cohort of Progressive Multiple Sclerosis Patients.Biomolecules · 2025Article
- Impact of preanalytical factors on blood CHI3L1 levels.Frontiers in immunology · 2025Article
- Review
- Inflammatory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes.Journal of neuroinflammation · 2024Article
- The Peripheral Profile of the Chitinase 3-like-1 in Benign Multiple Sclerosis - A Single Centre's Experience.CNS & neurological disorders drug targets · 2024Observational
- From progression to progress: The future of multiple sclerosis.Journal of central nervous system disease · 2024Article
- Spatial transcriptomics and neurofilament light chain reveal changes in lesion patterns in murine autoimmune neuroinflammation.Journal of neuroinflammation · 2023Article
- Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis.Nature communications · 2023Article
- Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.